1 633

Cited 19 times in

Prognostic Values of Vascular Endothelial Growth Factor and Matrix Metalloproteinase-2 in Hepatocellular Carcinoma after Radiotherapy

 Suh Y.-G.  ;  Lee E.-J.  ;  Cha H.  ;  Yang S.-H.  ;  Seong J. 
 DIGESTIVE DISEASES, Vol.32(6) : 725-732, 2014 
Journal Title
Issue Date
Adult ; Aged ; Analysis of Variance ; Biomarkers, Tumor/analysis* ; Carcinoma, Hepatocellular/blood ; Carcinoma, Hepatocellular/mortality ; Carcinoma, Hepatocellular/radiotherapy* ; Cohort Studies ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Liver Neoplasms/blood ; Liver Neoplasms/mortality ; Liver Neoplasms/radiotherapy* ; Male ; Matrix Metalloproteinase 2/urine* ; Middle Aged ; Predictive Value of Tests ; Prognosis ; Proportional Hazards Models ; Prospective Studies ; Republic of Korea ; Risk Assessment ; Survival Analysis ; Treatment Outcome ; Vascular Endothelial Growth Factor A/blood*
Hepatocellular carcinoma ; Matrix metalloproteinase-2 ; Radiotherapy ; Vascular endothelial growth factor
Objectives: Hepatocellular carcinoma (HCC) is a highly vascularized tumor. In this study, we investigated the prognostic and predictive values of proangiogenic factors in HCC patients receiving radiotherapy. Methods: Between September 2008 and December 2009, a total of 50 patients treated with radiotherapy were prospectively enrolled in this study. Serum and urine samples were collected <1 week before and after radiotherapy. Results: After completion of radiotherapy, serum vascular endothelial growth factor (VEGF)/platelet (Plt) levels were significantly increased (p < 0.01). Patients who experienced hepatic tumor recurrence outside the radiation field showed higher VEGF-A/Plt levels before and after radiotherapy than patients who did not (p = 0.04), whereas patients who had hepatic tumor recurrence inside the radiation field showed significantly higher matrix metalloproteinase (MMP)-2 levels after radiotherapy (p = 0.04). On multivariate analyses, a high level of either VEGF/Plt or MMP-2 (≥median) before radiotherapy was a significant independent prognostic factor for a worse progression-free survival (p = 0.04). Conclusions: In HCC patients receiving radiotherapy, levels of VEGF/Plt and MMP-2 before radiotherapy can be useful to predict treatment outcome. This study also suggests the necessity of anti-angiogenic therapy, such as sorafenib, since radiotherapy increases VEGF/Plt levels, and higher levels of VEGF/Plt are associated with a poor outcome.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Research Institute (부설연구소) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Suh, Yang Gun(서양권)
Seong, Jin Sil(성진실) ORCID logo https://orcid.org/0000-0003-1794-5951
Yang, Seung Hyun(양승현) ORCID logo https://orcid.org/0000-0002-0909-7828
Lee, Eun Jung(이은정)
Cha, Ji Hye(차지혜)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.